Circadian-system alterations during cancer processes: A review

International Journal of Cancer

Volumn 70, Issue 2, 1997, Pages 241-247

  Mormont, M C ^a   Levi F ^a  

^a Lab 'Rythmes Biologiques C   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CIRCADIAN RHYTHM; DNA REPLICATION; DNA, NEOPLASM; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RATS;

EID: 1842293964     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970117)70:2<241::AID-IJC16>3.0.CO;2-L     Document Type: Article

References (70)

1. ABRAHAMSEN, J.F., SMAALAND, R., SANDBERG, S., AAKVAAG, A. and LOTE, K., Circadian variation in serum cortisol and circulating neutrophils are markers for circadian variation of bone-marrow proliferation in cancer patients. Europ. J. Haematol., 50, 206-212 (1993).
2. BADRAN, A.J. and ECHAVE LLANOS, J.M., Persistence of mitotic circadian rhythm of a transplantable mammary carcinoma after 35 generations: its bearing on the success of treatment with endoxan. J. nat. Cancer Inst., 35, 285-290 (1965).
3. BAILLEUL, F., LÉVI, F., REINBERG, A. and MATHÉ, G., Interindividual differences in the circadian hematologic time structure of cancer patients. Chronobiol. Int., 3, 47-54 (1986).
4. BARBASON, H. and BETZ, E.H., Liver-cell control after discontinuation of DENA feeding in hepatocarcinogenesis. Europ. J. Cancer, 17, 149-156 (1980).
5. BARBASON, H., DE PAERMENTIER, F. and VAN CANFORT, J., Molecular regulatory mechanisms of nyctohemeral rhythms in hepatic-cell division and function. In: R. Gilles (ed.). Animal and environmental fitness, pp. 145-162, Pergamon Press, New York, Oxford (1980).
6. BARTSCH, C., BARTSCH, H., BELLMANN, O. and LIPPERT, T.H., Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer, 67, 1681-1684 (1991).
7. BARTSCH, C., BARTSCH, H., FLÜCHTER, S.H., ATTANASIO, A. and GUPTA, D., Evidence for modulation of melatonin secretion in men with bengin and malignant tumors of the prostate: relationship with the pituitary hormones. J. pineal Res., 2, 121-132 (1985).
8. BARTSCH, C., BARTSCH, H., FLÜCHTER, S.H., MECKE, D. and LIPPERT, T.H., Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Ann. NY Acad. Sci., 719, 502-525 (1994).
9. BENAVIDES, M., Cancer avancé de l'ovaire: approche chronobiologlque comme nouvelle stratégie du traitement et de la surveillance clinique et biologique. Dissertation, University of Paris (1991).
10. BEREZKIN, M.V., A comparative study of the circadian rhythm of mitotic activity in neoplasia and normal tissues. Bull. eksp. Biol. Med., 70, 83-84 (1970).
11. BLANK, M.A., GUSHCHIN, V.A., HALBERG, F., PORTELA, A. and CORNELISSEN, G., X-irradiation chronosensitivity and circadian rhythmic proliferation in healthy and sarcoma-carrying rats' bone marrow. In vivo, 9, 395-400 (1995).
12. BOUZAHZAH, B., Influence de différents promoteurs sur la prolifération cellulaire du foie de rat normal et précancéreux: rôle des corticoïdes et des rythmes circadiens. Dissertation University of Liège (1990).
13. BRUGUEROLLE, B., LÉVI, F., ARNAUD, C., BOUVENOT, G., MECHKOURI, M., VANNETZEL, J.M. and TOUITOU, Y., Alteration of physiologic circadian time structure of six plasma proteins in patients with advanced cancer. Ann. Rev. Chronopharmacol., 3, 207-210 (1987).
14. BURNS, R.E., SCHEVING, L.E. and TSAI, T.H., Orcadian rhythms in DNA synthesis and mitosis in normal mice and in mice bearing the Lewis lung carcinoma. Europ. J. Cancer, 15, 233-242 (1979).
15. DEKA, A.C., Application of chronobiology to radiotherapy of tumors of the oral cavity, Thesis, Post-graduate Institute of Medical Education and Research, Chandigarh, India (1975).
16. DEPRÉS-BRUMMER, P., LÉVI, F., METZGER, G. and TOUITOU, Y., Light-induced suppression of the rat circadian system. Amer. J. Physiol., 268, r1111-r1116 (1995).
17. FOCAN, C., Rythme nyctéméral de la division et chimiothérapie de synchronisation-recrutement en cancérologie clinique. Rev. méd. Liège, 30, 461-467 (1975).
18. FOCAN, C., BARBASON, H. and BETZ, E.H., Mise en évidence d'un rythme nyctéméral de la division cellulaire dans des sarcomes induits par le méthylcholanthrène. C.R. Acad. Sci. Paris, 276, 2229-2232 (1973).
19. FOCAN, C., SCHYNS-MOSEN, J., LUYCKX, A. and LEFÈBVRE, P., Circadian variability of kinetics in a transplantable islet-cell tumor of the golden hamster. J. Cancer Res. clin. Oncol., 104, 197-206 (1982).
20. FOCAN, C., COLLETTE, J., LÉVI, F., HRUSHESKY, W.J.M., TOUITOU, Y. and FRANCHIMONT, P., Circadian rhythms in human carcinoembryomc antigen (CEA), alphafetoprotein (APP) and prostatic acid phosphatase(PAP), evidence of chronopathology in cancer. Ann. Rev. Chronopharmacol., 3, 417-420 (1987).
21. GARCIA-SAINZ, M. and HALBERG, F., Mitotic rhythms in human cancer, re-evaluated by electronic computer programs - evidence for chronopathology. J. nat. Cancer Inst., 37, 279-292 (1966).
22. GAUTHERIE, M. and GROS, C., Circadian-rhythm alteration of skin temperature in breast cancer. Chronobiologia, 4, 1-17 (1977).
23. GULLINO, P.M., JAIN, R.K. and GRANTHAM, F.H., Temperature gradients and local perfusion in a mammary carcinoma. J. nat. Cancer Inst., 68, 519-533 (1982).
24. HALBERG, F., GEHRKE, C.W., KUO, K., NELSON, W.L., SOTHERN, R.B., CADOTTE, L.M., HAUS, E. and SCHEVING, L.E., Immunocytoma effect upon circadian variation in murine urinary excretion of B-aminoisobutiric acid, B-alanine, phenylalanine and tyrosine. Chronobiohgia, 5, 263-276 (1978).
25. HALBERG, F., HAUS, E., CARDOSO, S.S., SCHEVING, L.E., KÜHL, J.F.W., SHIOTSLIKA, R., ROSENE, R., PAULY, J.E., RUNGE, W., SPALDING, J.F., LEE, J.K. and GOOD, R.A., Towards chronotherapy of neoplasia: tolerance to treatment depends upon host rhythms. Experientia, 29, 909-934 (1973).
26. HALLEK, M., EMMERICH, B., REICHIE, A., SCHICK. H.D., SENEKOWITSCH, R. and REINBERG, A., Observation of circadian variations of serum thymidinekinase levels in control and tumor patients. Ann. Rev. Chronopharmacol, 5, 361-365 (1988).
27. HARRIS, B.E., SONG, R., SOONG, S. and DIASIO, R.B., Relationship between dihydropyrimidine-dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50, 197-20) (1990).
28. HORI, K., ZHANG, Q.H., Li, H.C., SAITO, S. and SATO, Y., Timing of cancer chemotherapy based on circadian variations in tumor-tissue blood flow. Int. J. Cancer, 65, 360-364 (1996).
29. HORI, K., ZHANG, Q.H. and SAITO, S., Variation of growth rate of rat tumor during a light-dark cycle: correlation with circadian fluctuation in tumor blood flow. Brit. J. Cancer, 71, 1163-1168 (1995).
30. HRUSHESKY, W.J.M., Circadian timing of cancer chemotherapy. Science, 228, 73-75 (1985).
31. HRUSHESKY, W.J.M., The multifreuuency (circadian, fertility, cycle and season) balance between host and cancer. Ann. NY Acad. Sci., 618, 228-255 (1991).
32. HRUSHESKY, W.J.M., BORCH, R. and LÉVI, F., Circadian timing dependence of cisplatin urinary kinetics. Clin. Phannacol. Ther., 32, 330-339 (1982).
33. HRUSHESKY, W.J.M., HAUS, E., LAKATUA, D.J., HALBERG, F., LANGEVIN, T.R. and KENNEDY, B.J., Marker rhythms for cancer chrono-chemotherapy. In: E. Haus and H. Rabat (eds.), Chronobiology 1982-1983, pp. 493-499, Karger, Basel (1984).
34. HRUSHESKY, W.J.M., VON ROEMELING, R., LANNING, R.M. and RABATIN, J.T., Orcadian-shaped infusions of floxuridine for progressive metastatic renal-cell carcinoma. J clin. Oncol. 8, 1504-1513 (1990).
35. KAMPFSCHMIDT, R.F. and UPCHURCH, H.F., Daily variation of body temperature, liver catalase activity, and plasma iron concentration in normal and tumor-bearing rats. Proc. Soc. exp. Biol. Med., 134, 527-529 (1970).
36. KISHIMOTO, R., TERASAWA, K., SAKAMGTO, Y. and NAKATA. Y., Shift of circadian metabolic rhythm in BFO-osteosarcoma-bearing mice. Jap. J. Cancer Res., 76, 284-288 (1985).
37. KLEVECZ, R.R. and BRALY, P.S., Circadian and ultradian cytokinetic rhythms of spontaneous human cancer. Ann. NY Acad. Sci., 618, 257-276 (1991).
38. KLEVECZ, R.R., SHYMKO, R.M., BLUMENFELD, D. and BRALY, P.S., Circadian gating of S phase in human ovarian cancer. Cancer Res., 47, 6267-6271 (1987).
39. LAKATUA, D.J., WHITE, M., SACKETT-LUNDEEN, L. and HAUS, E., Changes in phase relations of circadian rhythms in cell proliferation induced by time-limited feeding in mice bearing a rransplamabJe Harding-Passey tumor. Cancer Res., 43, 4068-4072 (1983).
40. LÉVI, F., BENAVIDES, M., CHEVELLE, C., LE SAUNIER, F., BAJLLEUL, F., MISSET, J.L., REGENSBERG, C., VANNETZEL, J.M., REJNBERG, A. and MATHÉ, G., Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase-Il trial with an evaluation of circadian timing and dose-intensity. J. clin. Oncol., 9, 705-714 (1990).
41. LÉVI, F., HALBERG, F., HAUS, E., SANCHEZ DE LA PENA, S., SOTHERN. R.B., HALBERG, E., HRUSHESKY, W.J.M., BROWN, H., SCHEVING, L.E. and KENNEDY, B.J., Synthetic adrenocorticotropin for optimizing murine circadian chronotoierance for adriamycin. Chronobiologia, 7, 227-244 (1980).
42. LÉVI, F. and 12 OTHERS, A chronopharmacologic phase II clinical trial with 5-fluorouracil. folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer, 69, 893-900 (1992).
43. LÉVI, F. and 16 OTHERS, Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid in patients with colorectal-cancer metastases: a randomized multi-institutional trial. J. nat. Cancer Inst. 86, 1608-1617 (1994).
44. MANSFIELD, C.M., CARABASI, R.A., WELLS, W. and BORMAN, K., Circadian rhythm in the skin temperature of normal and cancerous breasts, Int. J. Cancer, 1, 235-243 (1973).
45. MORMONT, M.C., BOUGHATTAS, N. and LÉVI. F., Mechanisms of circadian rhythms in the toxicity and the efficacy of anti-cancer drugs: relevance for the development of new analogs. In: B. Lemmer (ed.), Chronopharmacology: cellular and biochemical interactions, pp. 395-437, Marcel Dekker, New York (1989).
46. MORMONT, M.C., DE PRINS, J. and LÉVI, F., Assessment of activity circadian rhythms by wrist actigraphy: preliminary results in 30 patients with colorectal cancer. Pathol. Biol. (Paris), 44, 165-171 (1996a).
47. MORMONT, M.C., LÉVI, F., DEPRÉS-BRUMMER, P., GIACCHETTI, S., GRUIA, G., BLEUZEN, P., JASMIN, C. and MISSET, J.L., Rest-activity circadian rhythm, an objective measure for performance status and a strong indicator for quality of life. Proc. Amer. Soc. clin. Oncol., 15, 508 (1996b).
48. MOSKALIC, K.G., Duration of mitosis and diurnal rhythm of cell division in Ehrlich tumor and lymphoma NK-Ly. Bull eksp. Biol Med., 75, 99-102 (1973).
49. NASH, R.E. and ECHAVE LLANOS, J.M., Twenty-four-hour variations in DNA synthesis of a fast-growing and a slow-growing hepatoma: DNA synthesis rhythm in hepatoma. J. nat. Cancer Inst., 47, 1007-1012 (1971).
50. NELSON, W.L., ZINNEMAN, H., SELDEN, J., SHAPER, K., HALBERG, F. and BAZIN, H., Orcadian rhythm in Bence-Jones protein excretion by Lou rats bearing a transplantable immunocytoma, responsive to adriamycin treatment, Int. J. Chronobiol, 2, 359-365 (1974).
51. NERI, B., CIAPINI, A., COMPARINI, T., GUIDU G., GUIDI, S., LUPL R. and ROMANO, S., Circadian variations in phophohexose-isomerase (PGI) in multiple myeloma. Europ. J. Cancer clin. Oncol, 17, 1177-1181 (1981).
52. PETROVIC, A., OUDET, C. and STUTZMANN, J., Ultradian mitotic rhythms in culture of human sarcomatous bone cells originating from the patient before and after chemotherapy. Chronobiol. int., 6, 173-183 (1989).
53. POSTON, G.J., SAYDJARI, R., LAWRENCE, J.P., TRUDEL, J.L., RUBIN, N.H., TOWNSEND, C.M. and THOMPSON, J.C., Persistence of the circadian variation and altered response to hepatecromy of hepatic ornithine-decarboxylase activity with malignant tumor burden. Cancer Invest., 11, 400-407 (1993).
54. POTTER, V.R., WATANABE, M., PITOT, H.C. and MORRIS, H.P, Systematic oscillations in metabolic activity in rat liver and hepatomas. Survey of normal diploid and other hepatoma lines. Cancer Res., 29, 55-78 (1969).
55. RYDELL, R., WENNERBERG, J. and WILLEN, R., Circadian variation in the cell-cycle phase distribution in a squamous-cell-carcinoma xenograft; effects of cisplatin and fluorouracil treatment. In vivo, 4, 385-390 (1990).
56. SCALABRINO, G., FERIOLI, ME., PUERARI, M., MODENA, D., FRASCHINI, F. and MAJORINO, G., Changes in the circadian rhythm of ornithine decarboxylase in rat liver during chemical hepatocarcinogenesis. J. nat. Cancer Inst., 66, 697-702 (1981).
57. SKENE, D.J., BOJKOWSKI, C.J., CURRIE, J.E., WRIGHT, J., BOULTER, P.S. and ARENDT, J., 6-sulphatoxymelatonin production in breast-cancer patients. J. pineal Res., 8, 269-276 (1990).
58. SMAALAND, R., ABRAHAMSEN, J.F., SVARDAL, A.M., LOTE, K. and UELAND, P.M., DNA cell-cycle distribution and (GSH) content according to circadian stage in bone marrow of cancer patients. Brit. J. Cancer, 66, 39-45 (1992).
59. SMAALAND, R., LOTE, K., SOTHERN, R.B. and LAERUM, O.D., DNA synthesis and ploidy in non-Hodgkin's lymphoma demonstrate interpatient variation depending on circadian stage of cell sampling. Cancer Res., 53, 3129-3138 (1993).
60. SOKOLOWA, I.V., Circadian changes in mitotic activity ana DNA synthesis in rat neoplastic and normal tissues. Bull. eksp. Biol. Med., 76, 64-67 (1973).
61. SOTHERN, R.B., HRUSHESKY, W.J.M., HALBERG, F., HAUS, E. and KENNEDY, B.J., Circadian temperature rhythm in LOU rats with and without immunocytoma during polychronochemotherapy with adriamycin and cis-diamminedichloroplatinum. Chronobiologia, 5, 216 (1978).
62. STOLL, B.A. and BURCH, W.M., Surface detection of circadian rhythm in 32P content of cancer of the breast. Cancer, 21, 193-196 (1968).
63. TAHTI, E., Studies of the effect of X-radiation on 24-hour variations in the mitotic activity in human malignant tumours. Acta pathol. microbiol scand, suppl., 117, 1-166 (1956).
64. TAMARKIN, L., DANFORTH, D., LICHTER, A., DEMoss, E., COHEN, M., CHABNER, B. and LIPPMAN, M., Decreased nocturnal plasma melatonin peak in patients with estrogen-receptor-positive breast cancer. Science, 216, 1003-1005 (1982).
65. TIBAUX, FIRKET, H. and BARBASON, H., Analyse par simulation sur ordinateur de la cinétique cellulaire du foie. Pathol. Biol. (Paris), 44, 183-188 (1996).
66. TOUITOU, Y., LÉVR, F., BOGDAN, A., BENAVIDES, M., BAILLEUL, F. and MISSET, J.L., Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. J. Cancer Res. din. Oncol., 121, 181-188 (1995).
67. VITATERNA, M.H., KING, D.P., CHANG, A.M., KoRNHAUSER, J.M. and LOWREY, J.D., Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science, 264, 719-725 (1994).
68. VOUTILAINEN, A., Ueber die 24-Stunden Rhythmik der mitosen Frequenz von malignen Tumoren, Acta pathol. microbiol. scand. suppl., 99, 1-104 (1953).
69. WALDROP, R.D., SAYDJARI, R., RUBIN, N.H., RAYEORD, P.L., TOWNSEND, C.M. and THOMPSON, J.C., DNA synthetic activity in tumor-bearing mice. Chronobiol. int., 6, 237-243 (1989).
70. ZAGULA-MALLY, Z.W., CARDOSO, S.S., WILLIAMS, D., SIMPSON, H. and REINBERG, A., Time-point differences in skin mitotic activity of actinic keratoses and skin cancers. In: A. Reinberg and F. Halberg (eds.), Chronopharmacology, pp. 399-402, Pergamort Press, New York (1979).